1. Home
  2. DCO vs DFTX Comparison

DCO vs DFTX Comparison

Compare DCO & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ducommun Incorporated

DCO

Ducommun Incorporated

HOLD

Current Price

$141.97

Market Cap

1.9B

Sector

Industrials

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$21.92

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DCO
DFTX
Founded
1849
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
DCO
DFTX
Price
$141.97
$21.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$153.60
$38.50
AVG Volume (30 Days)
190.8K
1.9M
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$824,730,000.00
N/A
Revenue This Year
$7.40
N/A
Revenue Next Year
$8.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.85
N/A
52 Week Low
$58.10
$14.62
52 Week High
$145.90
$26.25

Technical Indicators

Market Signals
Indicator
DCO
DFTX
Relative Strength Index (RSI) 57.59 55.19
Support Level $87.68 $16.37
Resistance Level N/A $26.25
Average True Range (ATR) 5.39 1.53
MACD -0.26 -0.29
Stochastic Oscillator 63.08 27.59

Price Performance

Historical Comparison
DCO
DFTX

About DCO Ducommun Incorporated

Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: